Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Euroimmun and Xpedite Diagnostics Partner to Offer Faster, Easier Protocols for DNA Extraction at POC

By LabMedica International staff writers
Posted on 19 Dec 2023

EUROIMMUN (Lübeck, Germany) and Xpedite Diagnostics (Hallbergmoos, Germany) have entered into a strategic partnership for offering faster and easier protocols for DNA extraction at the point-of-care. Current users of the EUROArray diagnostic platform will now have access to the EUROArray SwiftX-traction Kit designed for rapid manual DNA extraction. EUROArray SwiftX-traction significantly reduces the complexity as well as processing time of the DNA extraction. It can extract DNA from different challenging sample types using just a few steps that take less than 30 minutes.

The new extraction method is currently being validated in combination with various CE-marked EUROArray products. Xpedite Diagnostics aims to soon register the extraction kit itself as a CE-IVD device under the European IVD Regulation 2017/746. Xpedite Diagnostics’ partnership with EUROIMMUN demonstrates its technical leadership in offering high-performing and user-friendly nucleic acid extraction solutions. This, combined with its strong expertise in quality management and regulatory affairs, makes Xpedite Diagnostics well-positioned to act as a reliable and efficient contract developer as well as manufacturer for other IVD companies.

“EUROArray SwiftX-traction was tailored specifically to the needs of users of the EUROArray diagnostic platform and is based on our SwiftX Toolbox,” said Dr. Andy Wende, CEO and Head of R&D at Xpedite Diagnostics GmbH. “The development was finished in only a few months and will result in a CE-IVD marked DNA extraction kit. It merges several advantages such as high sensitivity, short workflows, and improved usability. EUROArray SwiftX-traction will enhance customer satisfaction and acceptance, ultimately leading to a better sales position of the EUROArray diagnostic platform in the segments Dermatomycosis, STI testing, and HPV typing.”

Related Links:
EUROIMMUN 
Xpedite Diagnostics 

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.